Intravesical PPM Therapy for NMIBC
A Phase I clinical trial is evaluating the safety, tolerability, dose, and preliminary efficacy of PLZ4‑coated paclitaxel‑loaded nanoscale micelle (PPM) intravesical therapy in patients with non‑muscle‑invasive bladder cancer refractory to BCG.
This Phase I trial evaluates the safety, tolerability, dose, and preliminary efficacy of PLZ4‑coated paclitaxel‑loaded nanoscale micelle (PPM) intravesically in patients with non‑muscle‑invasive bladder cancer refractory to BCG.
Non‑muscle‑invasive bladder cancer has limited treatment options after BCG failure; this micelle therapy may target cancer cells specifically and reduce systemic toxicity.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.